P. Kishnani Et Al. , "The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks," MOLECULAR GENETICS AND METABOLISM , vol.135, no.2, 2022
Kishnani, P. Et Al. 2022. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks. MOLECULAR GENETICS AND METABOLISM , vol.135, no.2 .
Kishnani, P., Diaz-Manera, J., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, V., ... Toscano, A.(2022). The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks. MOLECULAR GENETICS AND METABOLISM , vol.135, no.2.
Kishnani, Priya Et Al. "The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks," MOLECULAR GENETICS AND METABOLISM , vol.135, no.2, 2022
Kishnani, Priya Et Al. "The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks." MOLECULAR GENETICS AND METABOLISM , vol.135, no.2, 2022
Kishnani, P. Et Al. (2022) . "The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks." MOLECULAR GENETICS AND METABOLISM , vol.135, no.2.
@article{article, author={Priya Kishnani Et Al. }, title={The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks}, journal={MOLECULAR GENETICS AND METABOLISM}, year=2022}